William Blair starts coverage on Compass Therapeutics, saying its lead drug could reshape bile duct cancer treatment and ...

Sydney Towle has continued to speak about her mental health throughout treatment for her stage 4 cholangiocarcinoma ...

Gallbladder cancer is a rare and often aggressive malignancy that develops in the tissues of the gallbladder — a small, pear-shaped organ located beneath the liver. The gallbladder stores bile, a ...

A recent study published in the journal Microorganisms explores the microbiome composition in patients with biliary tract cancer. Study: Interplay between the Human Microbiome and Biliary Tract Cancer ...

A 25-year-old woman who’d been healthy and active until she suddenly developed bile duct cancer has written a final, poignant message announcing her death and urging people to “enjoy the little things ...

Adding liposome-encapsulated irinotecan to standard chemotherapy failed to improve survival as second-line treatment for advanced biliary cancer, a small randomized study showed. Median ...

When do you have tests for bile duct cancer? Bile duct cancer is also called cholangiocarcinoma. It is a rare type of cancer that develops in the bile ducts. Most people are diagnosed with bile duct ...

Surgery and chemotherapy together improved survival in GIST patients with liver metastases, increasing median cancer-specific ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Zanidatamab exhibited durable antitumor activity among patients with previously treated advanced ...

Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Wednesday granted accelerated approval to zanidatamab ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...